Background and Methods The efficacy and safety of rotigotine transdermal patch in Parkinson’s disease (PD) were studied in some clinical trials. We performed a systematic review and meta-analysis of randomized controlled trials to evaluate the efficacy, tolerability, and safety of rotigotine transdermal patch versus placebo in PD. Results Six randomized controlled trials (1789 patients) were included in this meta-analysis. As compared with placebo, the use of rotigotine resulted in greater improvements in Unified Parkinson’s Disease Rating Scale activities of daily living score (weighted mean difference [WMD] –1.69, 95% confidence interval [CI] –2.18 to –1.19), motor score (WMD –3.86, 95% CI –4.86 to –2.86), and the activities of daily living and motor subtotal score (WMD –4.52, 95% CI –5.86 to –3.17). Rotigotine was associated with a significantly higher rate of withdrawals due to adverse events (relative risk [RR] 1.82, 95% CI 1.29–2.59), and higher rates of application site reactions (RR 2.92, 95% CI 2.29–3.72), vomiting (RR 5.18, 95% CI 2.25–11.93), and dyskinesia (RR 2.52, 95% CI 1.47–4.32) compared with placebo. No differences were found in the relative risks of headache, constipation, back pain, diarrhea, or serious adverse events. Conclusions Our meta-analysis showed that the use of rotigotine can reduce the symptoms of PD. However, rotigotine was also associated with a higher incidence of adverse events, especially application site reactions, compared with placebo.
References
[1]
Ferrer I, Martinez A, Blanco R, Dalfó E, Carmona M (2011) Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease. J Neural Transm 118: 821–839.
[2]
Zhang ZX, Roman GC, Hong Z, Wu CB, Qu QM, et al. (2005) Parkinson’s disease in China: prevalence in Beijing, Xian, and Shanghai. Lancet 365: 595–597.
[3]
Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, et al. (2004) Levodopa in the treatment of Parkinson’s disease: current controversies. Mov Disord 19: 997–1005.
[4]
Goetz CG, Poewe W, Rascol O, Sampaio C (2005) Evidence-based medical review update: pharmacological and surgical treatments of Parkinson’s disease: 2001 to 2004. Mov Disord 20: 523–539.
[5]
Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, et al. (2004) Pramipexole vs levodopa as initial treatment for Parkinson’s disease: a 4-year randomized controlled trial. Arch Neurol 61: 1044–1053.
[6]
Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, et al. (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med 342: 1484–1491.
[7]
Lees AJ, Katzenschlager R, Head J, Ben-Shlomo Y (2001) Ten-year follow-up of three different initial treatments in de-novo PD. a randomized trial. Neurology 57: 1687–1694.
[8]
Schrag A, Quinn N (2000) Dyskinesias and motor fluctuations in Parkinson’s disease. A community-based study. Brain 123: 2297–2305.
[9]
Poewe W, Wenning G (2002) Levodopa in Parkinson’s disease: mechanisms of action and pathophysiology of late failure. In: Jankovic J, Tolosa E, editors. Parkinson’s disease and movement disorders. Philadelphia: Lippincott Williams & Wilkins. 104–115.
[10]
Jenner P (2005) A novel dopamine agonist for the transdermal treatment of Parkinson’s disease. Neurology 65: S3–5.
[11]
Metman LV, Gillespie M, Farmer C, Bibbiani F, Konitsiotis S, et al. (2001) Continuous transdermal dopaminergic stimulation in advanced Parkinson’s disease. Clin Neuropharmacol 24: 163–169.
[12]
Braun M, Cawello W, Poole K, Horstmann R (2005) Steady-state pharmacokinetics of rotigotine in patients with early-stage Parkinson’s disease. Eur J Neurol 12: 96.
[13]
Elshoff JP, Braun M, Andreas JO, Middle M, Cawello W (2012) Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin Ther 34: 966–978.
[14]
Schnitzler A, Leffers KW, Hack HJ (2010) High compliance with rotigotine transdermal patch in the treatment of idiopathic Parkinson’s disease. Parkinsonism Relat Disord 16: 513–516.
[15]
Wüllner U, Kassubek J, Odin P, Schwarz M, Naumann M, et al. (2010) Transdermal rotigotine for the perioperative management of Parkinson’s disease. J Neural Transm 117: 855–859.
[16]
Quinn N, SP511 Investigators (2001) Rotigotine transdermal delivery system (TDS) (SPM962) - A multi-center, double-blind, randomized, placebo-controlled trial to assess the safety and efficacy of rotigotine TDS in patients with advances Parkinson’s Disease. Parkinsonism Relat Disord 7: S66.
[17]
Sanford M, Scott LJ (2011) Rotigotine Transdermal Patch A Review of its Use in the Treatment of Parkinson’s Disease. CNS Drugs 25: 699–719.
[18]
Jadad AR, Moore A, Carroll D, Jenkinson C, Reynolds DJM, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1–12.
[19]
The Parkinson Study Group (2003) A controlled trial of rotigotine monotherapy in early Parkinson’s disease. Arch. Neurol 60: 1721–1728.
[20]
Jankovic J, Watts RL, Martin W, Boroojerdi B (2007) Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch. Neurol 64: 676–682.
[21]
Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE (2007) Rotigotine transdermal patch in early Parkinson’s disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 22: 2398–2404.
[22]
LeWitt PA, Lyons KE, Pahwa R (2007) Advanced Parkinson disease treated with rotigotine transdermal system PREFER Study. Neurology 68: 1262–1267.
[23]
Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, et al. (2007) Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 6: 513–520.
[24]
Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, et al. (2011) Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 26: 90–99.
[25]
Baker WL, Silver D, White CM, Kluger J, Aberle J, et al. (2009) Dopamine agonists in the treatment of early Parkinson’s disease: A meta-analysis. Parkinsonism Relat Disord 15: 287–294.
[26]
Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI (2009) Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson’s disease: a meta analysis. Int J Clin Pract 63: 613–623.
[27]
Hauser RA, Auinger P (2011) Parkinson Study Group (2011) Determination of minimal clinically important change in early and advanced Parkinson’s disease. Mov Disord 26: 813–818.
[28]
Talati R, Reinhart K, Baker W, White CM, Coleman CI (2009) Pharmacologic treatment of advanced Parkinson’s disease: A meta-analysis of COMT inhibitors and MAO-B inhibitors. Parkinsonism Relat Disord 15: 500–505.
[29]
Oertel W, LeWitt P, Giladi N, Ghys L, Grieger F, et al. (2013) Treatment of patients with early and advanced Parkinson’s disease with rotigotine transdermal system: Age-relationship to safety and tolerability. Parkinsonism Relat Disord 19: 37–42.
[30]
Kulisevsky J, Pagonabarraga J (2010) Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson’s disease: meta-analysis of randomized controlled trials. Drug Saf 33: 147–161.
[31]
Cummings JL, Farlow MR, Meng X, Tekin S, Olin JT (2010) Rivastigmine transdermal patch skin tolerability: Results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer’s disease. Clin Drug Investig 30: 41–49.
[32]
UCB (2012) Neupro？ approved by U.S. FDA for Parkinson’s Disease and Restless Legs Syndrome [online]. Available from URL: http://www.ucb.presscentre.com/News/Neup？ro-approved-by-U-S-FDA-for-Parkinson-s-D？isease-and-Restless-Legs-Syndrome-2d6.as？px. Accessed 2012 April 3.
